NCT04541017 2025-10-16Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentNational Cancer Institute (NCI)Phase 1/2 Terminated8 enrolled 8 charts